Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Epiminder Ltd. ( (AU:EPI) ) just unveiled an announcement.
Epiminder has achieved a key milestone in its US expansion with the first American implantation of its Minder continuous EEG monitoring system at the Perelman School of Medicine at the University of Pennsylvania, as part of the DETECT randomized controlled trial in drug-resistant epilepsy. The study, which aims to enrol 210 patients across up to 25 US sites including three Mayo Clinic locations and Beth Israel Deaconess Medical Center, will compare Minder-based continuous EEG monitoring against standard of care to determine whether the technology better identifies clinically actionable events, potentially reshaping epilepsy management and strengthening Epiminder’s position in the global epilepsy diagnostics market.
More about Epiminder Ltd.
Epiminder Limited is a Melbourne-headquartered medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy and other seizure disorders that require continuous monitoring. Founded in 2017 by Professor Mark Cook in collaboration with the Bionics Institute, St Vincent’s Hospital, the University of Melbourne and Cochlear Limited, the company’s flagship product is Minder, a minimally invasive, long-term electroencephalography (EEG) monitoring system designed to provide continuous brain activity data while patients go about their normal daily lives, with operations in Australia and the United States.
Average Trading Volume: 228,984
See more insights into EPI stock on TipRanks’ Stock Analysis page.